Incyte said Nov. 13 it will not proceed with a planned Phase 3 ovarian cancer study, citing development priorities; the trial had been expected to start in the fourth quarter of 2026.
MAESTRA-3 was intended to evaluate INCB123667 and bevacizumab together as first-line maintenance therapy for ovarian cancer.
Incyte said the decision reflected how it is prioritizing its clinical development portfolio. Incyte said portfolio prioritization drove the decision, rather than safety or efficacy findings from the INCB123667 program.
Incyte does not expect the change to affect its financial guidance or previously disclosed long-term outlook.
